Mi Young Jeon

Mi Young Jeon

Auto-generated profile, based on publicly available information

Mi Young Jeon

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
MJMi Young Jeon
Mi Young Jeon
JPJun Chul Park
Jun Chul Park
KHKyu Yeon Hahn
Kyu Yeon Hahn
SSSung Kwan Shin
Sung Kwan Shin
Sang Kil LeeSang Kil Lee
Sang Kil Lee
YLYong Chan Lee
Yong Chan Lee

25 September 2019 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
DKDavid Sooik Kim
David Sooik Kim
MJMi Young Jeon
Mi Young Jeon
HLHye Won Lee
Hye Won Lee
BKBeom Kyung Kim
Beom Kyung Kim
JPJun Yong Park
Jun Yong Park
Seung Up KimSeung Up Kim
Seung Up Kim
The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. Of the total study population, 146 (43.7%) patients had HS (CAP > 238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA<12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P=0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P=0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P=0.022). CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.

30 May 2017 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
YPYong Eun Park
Yong Eun Park
BKBeom Kyung Kim
Beom Kyung Kim
JPJun Yong Park
Jun Yong Park
DKDo Young Kim
Do Young Kim
SASang Hoon Ahn
Sang Hoon Ahn
Seung Up KimSeung Up Kim
Seung Up Kim

15 September 2020 in Gut and Liver
Verified
Journal Article
Open access
PDF file
MSMin Je Sung
Min Je Sung
TLTae Seop Lim
Tae Seop Lim
MJMi Young Jeon
Mi Young Jeon
HLHye Won Lee
Hye Won Lee
BKBeom Kyung Kim
Beom Kyung Kim
Seung Up KimSeung Up Kim
Seung Up Kim
Min Je Sung, Tae Seop Lim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park, and Seung Up Kim. Gut and Liver 2020;14:626-35. https://doi.org/10.5009/gnl19126

21 February 2017 in Hepatology International
Verified
Journal Article
Closed access
PDF file
MJMi Young Jeon
Mi Young Jeon
HLHye Won Lee
Hye Won Lee
Seung Up KimSeung Up Kim
Seung Up Kim
JHJa Yoon Heo
Ja Yoon Heo
SHSojung Han
Sojung Han
KHKwang-Hyub Han
Kwang-Hyub Han

2 September 2017 in Liver International
Verified
Journal Article
Open access
PDF file
MJMi Young Jeon
Mi Young Jeon
HLHye Won Lee
Hye Won Lee
Seung Up KimSeung Up Kim
Seung Up Kim
BKBeom Kyung Kim
Beom Kyung Kim
JPJun Yong Park
Jun Yong Park
SASang Hoon Ahn
Sang Hoon Ahn
Background & Aims: Several risk prediction models for hepatocellular carcinoma (HCC) development are available. We explored whether the use of risk prediction models can dynamically predict HCC development at different time points in chronic hepatitis B (CHB) patients.Methods: Between 2006 and 2014, 1397 CHB patients were recruited. All patients underwent serial transient elastography at intervals of >6 months.Results: The median age of this study population (931 males and 466 females) was 49.0 years. The median CU‐HCC, REACH‐B, LSM‐HCC and mREACH‐B score at enrolment were 4.0, 9.0, 10.0 and 8.0 respectively. During the follow‐up period (median, 68.0 months), 87 (6.2%) patients developed HCC. All risk prediction models were successful in predicting HCC development at both the first liver stiffness (LS) measurement (hazard ratio [HR] = 1.067‐1.467 in the subgroup without antiviral therapy [AVT] and 1.096‐1.458 in the subgroup with AVT) and second LS measurement (HR = 1.125‐1.448 in the subgroup without AVT and 1.087‐1.249 in the subgroup with AVT). In contrast, neither the absolute nor percentage change in the scores from the risk prediction models predicted HCC development (all P > .05). The mREACH‐B score performed similarly or significantly better than did the other scores (AUROCs at 5 years, 0.694‐0.862 vs 0.537‐0.875).Conclusions: Dynamic prediction of HCC development at different time points was achieved using four risk prediction models, but not using the changes in the absolute and percentage values between two time points. The mREACH‐B score was the most appropriate prediction model of HCC development among four prediction models.